Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC By Ogkologos - January 30, 2026 261 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASCENT-04/KEYNOTE-D19 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping... July 1, 2024 FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma August 14, 2020 At NCI, A Robust and Rapid Response to the COVID-19 Pandemic April 17, 2020 Treating the Whole Person: How Cancer Centers Are Addressing Social Needs July 18, 2024 Load more HOT NEWS What to Know About Using Activated Charcoal During Cancer Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy... Cancer in My Community: Addressing Health Disparities in Brazil Coming Full Circle on Cancer and Extrachromosomal DNA
